[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hong Kong University of Science and Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":178},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,71,95,123,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100621873","predictors-of-clinical-outcomes-of-deep-brain-stimulation-in-parkinsons-disease-100621873",false,"NCT07376278","Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease","A Prospective Observational Study for the Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease","Inclusion Criteria:\n\n1. Diagnosis of \"Clinically Established PD\" as defined by the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (MDS-PD criteria)\n2. Referred for DBS according to standard local clinical guidelines 2a. Significant motor complications despite optimized pharmacological treatment 2ai. UPDRS motor score \\>30\u002F108 in the off-medication state 2aii. Hoehn and Yahr staging \\>2.5\u002F5 in the off-medication state 2b. Dopamine responsive 2bi. \\>33% improvement in UPDRS motor score after levodopa administration 2c. Age ≤75 years 2d. No contraindication to surgery or other significant comorbidity with limited life expectancy 2e. No significant psychiatric problems or cognitive impairment 2f. No structural lesions or features suggestive of atypical parkinsonism or other mimickers of idiopathic PD on neuroimaging\n\nExclusion Criteria:\n\n1. Unwilling to undergo blood sampling for study purposes\n2. Evidence of Parkinsonism due to heavy metal exposure\n3. History of neurodevelopmental disorder, neurodegenerative disease other than PD, CNS infection, neuroinflammatory disease (e.g. multiple sclerosis, CNS lupus), malignancy within the last 10 years, cerebrovascular accident, HIV infection, systemic autoimmune disease, alcohol dependence or other substance use\n4. Unable to pass DBS pre-operative assessment or unwilling to undergo DBS","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to identify factors in blood that are associated with response to deep brain stimulation (DBS) surgery in patients with Parkinson's disease. The main questions it aims to answer are:\n\n1. What factors in blood (proteins and RNA) are associated with good vs poor response to DBS?\n2. Are these factors able to predict response to DBS?\n3. How do these factors change before and after DBS?\n\nBlood and leftover brain tissue (which spontaneously adhere to the surgical instruments) will be taken and routine clinical data (including scores from routine assessments) will be collected from consenting participants who undergo DBS.",[26,27],"Deep Brain Stimulation","PARKINSON DISEASE (Disorder)",[29,30,31,32,33,34],"deep brain stimulation","DBS","Parkinson's disease","multiomic","transcriptomic","proteomic","RECRUITING","2026-02-23",{"date":38,"type":39},"2026-02-24","ACTUAL",{"date":41,"type":39},"2026-02-05",{"date":43,"type":21},"2038-02-01",{"name":45,"class":46},"Hong Kong University of Science and Technology","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100622294","artificial-intelligence-assisted-mds-updrs-assessment-for-parkinsons-disease-100622294","NCT07381751","Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson's Disease","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Diagnosis of \"Clinically Established PD\" as defined by the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (MDS-PD criteria) \\[12\\]\n3. Able to provide informed consent and willing to participate in video-recorded MDS-UPDRS Part III assessments\n4. No significant visual, auditory, or musculoskeletal impairments that would interfere with video-based motor assessments\n\nExclusion Criteria:\n\n1. Unwillingness to be video recorded for study purposes\n2. History of neurodevelopmental disorder, neurodegenerative disease other than PD, CNS infection, neuroinflammatory disease (e.g. multiple sclerosis, CNS lupus), malignancy within the last 10 years, cerebrovascular accident, HIV infection, systemic autoimmune disease, alcohol dependence or other substance use","95 Years",{"count":56,"type":21},500,"Idiopathic Parkinson's disease (PD) is a neurodegenerative disease that progressively causes both motor and non-motor symptoms. As the second most common neurodegenerative disease and most common movement disorder, it affects over 8.5 million people worldwide and 13,000 people in Hong Kong. The most classical symptoms of PD are resting tremors, rigidity of the muscles, bradykinesia (slowing of movement), and gait difficulty. Other symptoms include sleep disorders, psychiatric symptoms, cognitive impairment, and autonomic dysfunction. Its pathophysiology is marked by the loss of dopaminergic neurons and the accumulation of aggregates called Lewy bodies.\n\nThe severity of PD-related motor symptoms is usually semi-quantitatively (\"normal\", \"slight\", \"mild\", \"moderate\", and \"severe\") evaluated by expert physicians and physiotherapists according to the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III). However, the MDS-UPDRS III is semiquantitative and subjective, which might mask mild treatment effects or even provide false-positive results. Moreover, it takes significant time and effort for assessment with expected inter-observer variations.\n\nTo address these issues, various artificial intelligence (AI) technologies and telemedicine approaches have been investigated for patient evaluation. However, previous studies did not incorporate items assessing rigidity and postural stability, which require physical contact as per the MDS-UPDRS III instructions. Zhu et al. explored a motor symptom machine-rating system for the complete MDS-UPDRS III. Nevertheless, they employed a depth camera and conducted the tests within a strictly controlled ideal laboratory environment. For the widespread implementation of AI-assisted rating, the RGB camera is a more accessible alternative.",[59],"Parkinson Disease",[61],"artificial intelligence, MDS-UPDRS, Parkinson's disease","NOT_YET_RECRUITING","2026-01-26",{"date":65,"type":39},"2026-02-02",{"date":67,"type":21},"2026-03-01",{"date":69,"type":21},"2029-02-28",{"name":45,"class":46},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":47},"100620367","deciphering-the-factors-of-longevity-through-a-multi-omics-study-in-long-lived-individuals-in-hong-kong-100620367","NCT07356700","Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong","Inclusion Criteria:\n\n1. Han Chinese ethnicity\n2. Able to provide official evidence for being 95 years or older (e.g., a birth certificate)\n3. Mentally capable of consenting to join the study with or without informant presence\n4. Consent to donation of biospecimens (i.e., blood)\n\nExclusion Criteria:\n\n1. Mentally incapable of consenting to join the study even with the presence of an informant\n2. Refusal to provide blood samples",true,"65 Years",{"count":80,"type":21},2500,"Population aging is changing societal dynamics and poses significant global challenges. By 2050, an estimated 1.6 billion people worldwide will be over age 65. Because aging is the primary risk factor for many common chronic diseases, it is essential to reduce the burden of age-related illnesses and promote healthy aging. Hong Kong has one of the largest proportions of elderly adults and has the highest life expectancy in the world, with approximately 11,575 centenarians reported in 2021. Thus, the long-lived population in Hong Kong is a valuable resource for studying healthy aging.\n\nLongevity is a complex trait influenced by genetic, environmental, and behavioral factors. To unveil the mechanisms leading to longevity and healthy aging, researchers focused on centenarians who are extremely long living. Comparisons between long-lived individuals (LLIs) and others have identified several genetic factors and protein markers associated with longevity. Previous centenarian studies revealed that centenarians and their offsprings have a 5-fold lower risk of developing age-related diseases such as Alzheimer's disease and higher cognitive reserve. Certain protein signatures predict longer survival and centenarians acquire aging signatures much later than elderly in the general population. Certain healthy lifestyle leads to higher chance becoming centenarians, including never smoking, exercise and greater dietary diversity.\n\nDespite emerging studies on centenarian population, an integrated approach to understand diverse molecular signatures of longevity is still lacking. Moreover, most of the centenarian studies are based on European descents. To conclude, a multi-omics study examining the genetic, proteomic, metabolomic, and microbiota profiles of LLIs in Chinese population is necessary.\n\nHence, the study proposed herein aims to identify multi-omics biomarkers that can be used to monitor aging processes and related diseases. In addition, it will provide candidate modifiable factors to promote healthy aging, focusing on Chinese population and local Hong Kong population for the first time. Ultimately, the insights gained from this research will inform the development of effective strategies to enhance healthy aging and improve the quality of life of our local aging population.",[83],"Aging",[83,85,86,87],"Multi-omics","AI-based tool","Longevity","2026-01-20",{"date":90,"type":39},"2026-01-22",{"date":67,"type":21},{"date":93,"type":21},"2031-02-28",{"name":45,"class":46},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":77,"sex":16,"minAge":102,"maxAge":18,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":104,"conditions":105,"keywords":110,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100619665","neurocare-community-project-a-community-based-prospective-observational-study-for-early-alzheimers-detection-in-hk-100619665","NCT07347574","NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK","NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in Hong Kong","Inclusion Criteria:\n\n* Mentally capable of providing informed consent, with or without an informant present\n* Willing and able to undergo blood draw and complete study related assessments; willing to be contacted for follow-up\n\nExclusion Criteria:\n\n* Lacks capacity to consent even with an informant present\n* Refuses or is unable to provide blood samples or complete essential assessments\n* Currently enrolled in another clinical trial that could interfere with this study\n* Known illness that prevents longitudinal follow up or uncontrolled medical illness such as neurodevelopmental disorder, neurodegenerative disease, epilepsy, central nervous system infection, neuroinflammatory diseases, brain tumor, cerebrovascular diseases, history of major psychiatric illness, history of major head injury with altered consciousness, sexually transmitted disease including HIV and syphilis, visual and auditory disability, history of alcohol dependence, substance use disorder, systemic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, or malignancy.\n* Active delirium or evidence of reversible\u002Fsecondary causes of cognitive impairment (e.g., vitamin B12 deficiency, hypothyroidism) until treated\u002F stabilized","60 Years",{"count":80,"type":21},"Population aging is reshaping societal dynamics and presents significant global challenges. By 2050, it is projected that 1.6 billion people worldwide will be over the age of 65. Given that aging is the primary risk factor for many common chronic diseases, reducing the burden of age-related illnesses and promoting healthy aging have become critical public health priorities. Notably, Hong Kong has one of the largest proportions of elderly and the highest life expectancy in the world. Dementia, particularly Alzheimer's disease (AD), is a multifaceted condition influenced by both biological and behavioral factors. There is a paucity of robust, community-based prospective data in ethnic Chinese populations that integrate clinical and cognitive measures with objective biomarkers and neuroimaging, especially at earlier stages such as mild cognitive impairment (MCI) and early AD. This community-based project aims to establish a cohort of elderly in Hong Kong, with longitudinal follow-up for 2-3 years. A key strength of this research is the incorporation of a panel of blood biomarkers, which will provide a less invasive and more affordable screening tool to identify Alzheimer's disease at a much earlier stage in the community. Additionally, through benchmark with MRI and PET imaging gold standard, these biomarkers have the potential to predict the conversion risk 1) from clinically normal to mild cognitive impairment and Alzheimer's disease (AD dementia); 2) from clinically MCI to Alzheimer's disease (MCI-AD dementia) or remain static; and differentiate non-AD dementia from Alzheimer's disease (dementia-AD). Collectively, these data will facilitate monitoring of aging processes and cognitive decline, help to identify candidate modifiable factors associated with resilience, and generate a de-identified, Chinese-specific resource to advance healthy aging in Hong Kong.",[106,107,108,109],"AD - Alzheimer's Disease","Mild Cognitive Impairment","Normal Cognition","Dementia",[111,112,113,114,115],"Alzheimer's disease","PET imaging","MR imaging","Biomarker","Amyloid","2026-01-15",{"date":88,"type":39},{"date":119,"type":21},"2026-02-01",{"date":121,"type":21},"2030-12-30",{"name":45,"class":46},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":77,"sex":16,"minAge":102,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":133,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100597891","vr-based-multi-dimensional-intervention-on-cognitive-function-with-ai-agents-100597891","NCT07064382","VR-based Multi-dimensional Intervention on Cognitive Function, With AI-agents","VR-based Multi-dimensional Intervention on Cognitive Function and Well-beings","Inclusion Criteria:\n\n* older adults\n\nExclusion Criteria:\n\n* cannot attend physical activity like pedalling rehabilitation bike\n* other health issues (assessed by health professionals)","120 Years",{"count":132,"type":21},60,"INTERVENTIONAL",[135],"NA","Virtual Reality-based multi-dimensional intervention for cognition and well-being will be provided to older adults, with AI-agents. The digital health intervention include physical activity, gamification, cognitive trainings. Cognition, like memory, spatial function, sleepiness and mental health will be studied as outcomes.",[109,138,139,140],"Sleepiness","Mental Health","Alzheimer Disease","2025-07-03",{"date":143,"type":39},"2025-07-14",{"date":145,"type":21},"2025-07-15",{"date":147,"type":21},"2028-06-15",{"name":45,"class":46},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":77,"sex":16,"minAge":102,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":133,"phases":159,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100587925","phase-1-vr-based-physical-activity-and-reminiscence-therapy-100587925","NCT06934720","VR-based Physical Activity and Reminiscence Therapy","Active Physical Activity - Virtual Reality Cognitive Therapy","Inclusion Criteria:\n\n* older adults in the setting who have the ability to pedal the rehabilitation bike\n\nExclusion Criteria:\n\n* Individuals self-reporting or identified by stakeholders as unwilling or unsuitable to participate.","100 Years",{"count":158,"type":21},100,[160,161],"PHASE1","PHASE2","The goal of this clinical trial is to learn if active Physical activity + virtual reality cognitive therapy (aPAVRCT) works to slow the progression of AD cognitive decline in older adults. It will also learn about the physical effects and mental effects of the aPAVRCT. The main questions it aims to answer are:\n\nDoes aPAVRCT slow the progression of AD cognitive decline? (e.g., HK-MoCA, ADAS-Cog) Does aPAVRCT improve physical function? (e.g., ADL) Does aPAVRCT improve mental health? (e.g., GDS-15, PANAS) Does aPAVRCT improve life satisfaction? Does aPAVRCT improve other cognitive or physical capacities? What issues and benefits do participants and stakeholders (e.g., families, caregivers, managers) have when taking aPAVRCT? (e.g., NPI-Q) Researchers will compare the intervention group (aPAVRCT) to a control group (rehabilitation bike) to see if aPAVRCT works to slow the progression of AD in cognitive decline.\n\nParticipants will:\n\nTake aPAVRCT (interventional group) or usual physical acitvity (control group) at least twice a week, 15 minutes for each session, for 12-16 weeks Physiotherapies (assistants) and care professionals will do the intervention, research group will operate, observe, and assist the experiment.\n\nAll the experiment processes will be recorded. Visit the sites everyday for checkups and tests Keep a diary of their symptoms, the number of times, and any essential information\n\nSites: around 3-5 nursing homes, under one institution. Inclusion criteria: older adults in the setting who have the ability to pedal a rehabilitation bike.",[109,164,165,166,167,168,169],"Neurodegenerative Disease","Mild Cognitive Impairment (MCI)","Virtual Reality","Physical Activity","Alzheimer's Disease (AD)","Cognitive Therapy","2025-05-18",{"date":172,"type":39},"2025-05-22",{"date":174,"type":21},"2025-05-19",{"date":176,"type":21},"2027-04-15",{"name":45,"class":46},""]